Abstract Library

#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nessi C, Paiella S, Miotto M, Viviani E, Zingaretti C,

Keywords: somatostatin analogs, resectable pnets,

#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis

Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vercherat C

Authors: Vercherat C, Walter T, Massoma-Peh P, Bollard J, Lacheretz-Bernigaud A,

Keywords: neuroendocrine, therapy, Streptozotocin, mTOR pathway, combination, pre-clinical study,

#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance

Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Han X, Ji Y, Zhao J, Xu X, Lou W,

Keywords: pNET, mTOR, PTEN, ICH, clinical behavior, prognosis,